What's in Laboratorios Sophia S.A de C.V.'s pipeline?

Laboratorios Sophia S.A de C.V. has 24 drugs in our index: 13 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Laboratorios Sophia S.A de C.V.'s portfolio?

Top competitors by shared drug class: Allergan, Indiana University School of Medicine, Bausch & Lomb Incorporated, Carolina Eyecare Physicians, LLC, Federal University of São Paulo.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/laboratorios-sophia-s-a-de-c-v.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Laboratorios Sophia S.A de C.V. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Laboratorios Sophia S.A de C.V. pipeline: 13 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

13 marketed 0 filed 7 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Optive®	Optive®	marketed	Artificial tear / Ocular lubricant		Ophthalmology
Dorzolamide-timolol-brimonidine and latanoprost	Dorzolamide-timolol-brimonidine and latanoprost	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog	Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor	Ophthalmology
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)	Ophthalmology
Meticel Ofteno® 0.5%	Meticel Ofteno® 0.5%	marketed	Artificial tear / Ocular lubricant		Ophthalmology
Meticel Ofteno®	Meticel Ofteno®	marketed	Artificial tear / Ocular lubricant		Ophthalmology
Systane Ultra Preservative Free	Systane Ultra Preservative Free	marketed	Artificial tear / Ocular lubricant		Ophthalmology
Sodium hyaluronate 0.15%	Sodium hyaluronate 0.15%	marketed	Artificial tear / Ocular lubricant		Ophthalmology
PRO-155	PRO-155	marketed			Other
Manzanilla Sophia®	Manzanilla Sophia®	marketed
Sodium hyaluronate 0.4%	Sodium hyaluronate 0.4%	marketed
Zymar®	Zymar®	marketed
PRO-087	PRO-087	marketed			Other

Therapeutic area mix

Ophthalmology · 13
Other · 6
Ophthalmology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 3 shared drug classes
Indiana University School of Medicine · 2 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
Carolina Eyecare Physicians, LLC · 2 shared drug classes
Federal University of São Paulo · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
AbbVie · 2 shared drug classes
Johns Hopkins University · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Laboratorios Sophia S.A de C.V.:

Cite this brief

Drug Landscape (2026). Laboratorios Sophia S.A de C.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratorios-sophia-s-a-de-c-v. Accessed 2026-05-16.